Skip to content

Effects of Different Crystalloid Solutions for Extra-corporeal Membrane Oxygenator (ECMO) Priming

Effects of Different Crystalloid Solutions for Extra-corporeal Membrane Oxygenator (ECMO) Priming

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02609360
Enrollment
45
Registered
2015-11-20
Start date
2013-05-31
Completion date
Unknown
Last updated
2015-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Failure

Keywords

Acute Respiratory Failure, ARDS, ECMO, Lung transplantation, Acid-Base Equilibrium

Brief summary

Crystalloid solutions modify acid-base equilibrium according to their electrolyte composition. Moreover, it has been suggested that these alterations are generated by the difference between the solution strong ion difference (SID) and the plasma bicarbonate level. An increased risk of acute kidney injury and renal replacement therapy has been associated to the infusion of chloride rich crystalloids. This study aims to compare, in patients with acute respiratory failure undergoing ECMO support, the effects on acid-base status and renal function of crystalloids commonly employed for circuit priming to a balanced solution created with a SID equal to patients' bicarbonate level.

Interventions

OTHERPriming of ECMO circuit with 0.9% NaCl

0.9% NaCl as priming crystalloid solution

OTHERPriming of ECMO circuit with Ringer Lactate

Ringer Lactate as priming crystalloid solution

OTHERPriming of ECMO circuit with Balanced Solution

Balanced Solution as priming crystalloid solution

Sponsors

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with Acute Respiratory Failure in need for ECMO treatment

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Variation in Acid-Base Equilibrium (Base Excess)First 24 hours after ECMO start

Secondary

MeasureTime frame
Variation in Acid-Base Equilibrium (pH)First 24 hours after ECMO start
Variation in Renal FunctionFirst 24 hours after ECMO start

Countries

Italy

Contacts

Primary ContactPietro Caironi, MD
pietro.caironi@unimi.it+39-02-55033232

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026